A detailed history of Israel Englander (Millennium Management LLC) transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 797,511 shares of CHRS stock, worth $1.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
797,511
Previous 616,028 29.46%
Holding current value
$1.21 Million
Previous $1.07 Million 22.16%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.99 - $1.8 $179,668 - $326,669
181,483 Added 29.46%
797,511 $829,000
Q2 2024

Aug 14, 2024

SELL
$1.58 - $2.51 $1.01 Million - $1.61 Million
-641,335 Reduced 51.01%
616,028 $1.07 Million
Q1 2024

May 15, 2024

SELL
$2.02 - $3.14 $3.2 Million - $4.98 Million
-1,584,956 Reduced 55.76%
1,257,363 $3.01 Million
Q4 2023

Feb 14, 2024

BUY
$1.59 - $3.85 $3.16 Million - $7.66 Million
1,989,851 Added 233.42%
2,842,319 $9.46 Million
Q2 2023

Aug 14, 2023

BUY
$3.79 - $8.3 $2.4 Million - $5.26 Million
633,994 Added 290.19%
852,468 $3.64 Million
Q1 2023

May 15, 2023

SELL
$5.89 - $10.52 $1.91 Million - $3.41 Million
-324,147 Reduced 59.74%
218,474 $1.49 Million
Q4 2022

Feb 14, 2023

BUY
$5.69 - $10.07 $144,901 - $256,442
25,466 Added 4.92%
542,621 $4.3 Million
Q3 2022

Nov 14, 2022

BUY
$7.17 - $13.87 $916,684 - $1.77 Million
127,850 Added 32.84%
517,155 $4.97 Million
Q2 2022

Aug 15, 2022

BUY
$5.86 - $13.23 $1.1 Million - $2.48 Million
187,245 Added 92.67%
389,305 $2.82 Million
Q1 2022

May 16, 2022

SELL
$10.92 - $16.41 $1.4 Million - $2.11 Million
-128,381 Reduced 38.85%
202,060 $2.61 Million
Q4 2021

Feb 14, 2022

SELL
$15.81 - $18.99 $2.43 Million - $2.92 Million
-153,584 Reduced 31.73%
330,441 $5.27 Million
Q3 2021

Nov 15, 2021

BUY
$12.68 - $17.79 $2.99 Million - $4.2 Million
235,903 Added 95.08%
484,025 $7.78 Million
Q2 2021

Aug 16, 2021

SELL
$12.95 - $15.41 $2.01 Million - $2.39 Million
-155,288 Reduced 38.49%
248,122 $3.43 Million
Q1 2021

May 17, 2021

BUY
$14.42 - $21.39 $5.82 Million - $8.63 Million
403,410 New
403,410 $5.89 Million
Q2 2020

Aug 14, 2020

SELL
$14.43 - $19.16 $5.1 Million - $6.77 Million
-353,446 Closed
0 $0
Q1 2020

May 14, 2020

SELL
$11.67 - $22.53 $3.4 Million - $6.56 Million
-290,997 Reduced 45.15%
353,446 $5.73 Million
Q4 2019

Feb 14, 2020

BUY
$16.33 - $21.37 $9.31 Million - $12.2 Million
570,157 Added 767.52%
644,443 $11.6 Million
Q3 2019

Nov 14, 2019

SELL
$16.3 - $23.37 $1.69 Million - $2.42 Million
-103,441 Reduced 58.2%
74,286 $1.51 Million
Q2 2019

Aug 15, 2019

SELL
$13.1 - $22.1 $3.85 Million - $6.49 Million
-293,728 Reduced 62.3%
177,727 $3.93 Million
Q2 2019

Aug 14, 2019

SELL
$13.1 - $22.1 $3.6 Million - $6.08 Million
-274,907 Reduced 36.83%
471,455 $25.3 Million
Q1 2019

May 14, 2019

BUY
$8.38 - $15.5 $6.25 Million - $11.6 Million
746,362 New
746,362 $10.2 Million
Q4 2018

Feb 14, 2019

SELL
$8.65 - $16.28 $4.46 Million - $8.4 Million
-516,059 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$14.45 - $20.25 $179,960 - $252,193
12,454 Added 2.47%
516,059 $8.52 Million
Q2 2018

Aug 14, 2018

BUY
$10.25 - $17.45 $3.53 Million - $6.01 Million
344,240 Added 216.01%
503,605 $7.05 Million
Q1 2018

May 15, 2018

SELL
$9.1 - $13.7 $4.88 Million - $7.34 Million
-535,921 Reduced 77.08%
159,365 $1.76 Million
Q4 2017

Feb 14, 2018

BUY
$8.35 - $14.4 $5.2 Million - $8.97 Million
623,248 Added 865.17%
695,286 $6.12 Million
Q3 2017

Nov 14, 2017

BUY
$11.1 - $14.5 $799,621 - $1.04 Million
72,038
72,038 $962,000

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $118M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.